Back
Going beyond EGFR.
Journal article

Going beyond EGFR.

  • Zimmermann S Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
  • Peters S
  • 2012-09-19
Published in:
  • Annals of oncology : official journal of the European Society for Medical Oncology. - 2012
Adenocarcinoma
Anaplastic Lymphoma Kinase
Carcinoma, Non-Small-Cell Lung
Class I Phosphatidylinositol 3-Kinases
ErbB Receptors
Humans
Molecular Targeted Therapy
Mutation
Oncogene Proteins, Fusion
Phosphatidylinositol 3-Kinases
Protein-Tyrosine Kinases
Proto-Oncogene Proteins
Proto-Oncogene Proteins B-raf
Proto-Oncogene Proteins c-met
Proto-Oncogene Proteins p21(ras)
Receptor Protein-Tyrosine Kinases
Receptor, ErbB-2
ras Proteins
English a substantial proportion of non-small-cell lung cancer (NSCLC), and adenocarcinoma in particular, depends on a so-called 'driver mutation' for their malignant phenotype. This genetic alteration induces and sustains tumorigenesis, and targeting of its protein product can result in growth inhibition, tumor response and increased patient survival. NSCLC can thus be subdivided into clinically relevant molecular subsets. Mutations in EGFR best illustrate the therapeutic relevance of molecular classification. This article reviews the scope of presently known driving molecular alterations, including ROS1, BRAF, KRAS, HER2 and PIK3CA, with a special emphasis on aLK rearrangements, and outlines their potential therapeutic applications.
Language
  • English
Open access status
bronze
Identifiers
Persistent URL
https://sonar.ch/global/documents/20643
Statistics
Document views: 21 File downloads: